Nothing Special   »   [go: up one dir, main page]

BR112017016084A2 - composição e método para o tratamento da doença veno-oclusiva hepática - Google Patents

composição e método para o tratamento da doença veno-oclusiva hepática

Info

Publication number
BR112017016084A2
BR112017016084A2 BR112017016084A BR112017016084A BR112017016084A2 BR 112017016084 A2 BR112017016084 A2 BR 112017016084A2 BR 112017016084 A BR112017016084 A BR 112017016084A BR 112017016084 A BR112017016084 A BR 112017016084A BR 112017016084 A2 BR112017016084 A2 BR 112017016084A2
Authority
BR
Brazil
Prior art keywords
treatment
composition
occlusive disease
hepatic veno
veno
Prior art date
Application number
BR112017016084A
Other languages
English (en)
Inventor
Michael Freissmuth
Zahra Kazemi
Ursula Lemberger
Madeleine Themanns
Eva-Maria Zebedin-Brandl
Christoph Österreicher
Original Assignee
Scipharm Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipharm Sarl filed Critical Scipharm Sarl
Publication of BR112017016084A2 publication Critical patent/BR112017016084A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

?composição e método para o tratamento da doença veno-oclusiva hepática?. a presente invenção se refere a uma composição compreendendo um análogo, um derivado ou um sal farmaceuticamente aceitável de prostaciclina para utilização na prevenção ou no tratamento de síndrome da obstrução sinusoidal e/ou doença veno-oclusiva hepática (dvo).
BR112017016084A 2015-01-27 2016-01-27 composição e método para o tratamento da doença veno-oclusiva hepática BR112017016084A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15152665 2015-01-27
PCT/EP2016/051675 WO2016120311A1 (en) 2015-01-27 2016-01-27 Composition for the treatment of hepatic veno-occlusive disease

Publications (1)

Publication Number Publication Date
BR112017016084A2 true BR112017016084A2 (pt) 2018-03-27

Family

ID=52394992

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016084A BR112017016084A2 (pt) 2015-01-27 2016-01-27 composição e método para o tratamento da doença veno-oclusiva hepática

Country Status (14)

Country Link
US (1) US20180021347A1 (pt)
EP (1) EP3250289A1 (pt)
JP (1) JP2018503654A (pt)
KR (1) KR20170106360A (pt)
CN (1) CN107592811A (pt)
AU (1) AU2016212091A1 (pt)
BR (1) BR112017016084A2 (pt)
CA (1) CA2973147A1 (pt)
CL (1) CL2017001904A1 (pt)
EA (1) EA201791696A1 (pt)
IL (1) IL253390A0 (pt)
SG (1) SG11201705809QA (pt)
WO (1) WO2016120311A1 (pt)
ZA (1) ZA201704957B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5859433B2 (ja) 2009-06-12 2016-02-10 マンカインド コーポレイション 規定された比表面積を有するジケトピペラジン微粒子
EP4137127A1 (en) 2013-01-11 2023-02-22 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
KR102391750B1 (ko) 2013-03-15 2022-04-28 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
JP6491658B2 (ja) 2013-07-18 2019-03-27 マンカインド コーポレイション 熱安定性乾燥粉末医薬組成物及び方法
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
MX2021008943A (es) * 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.

Also Published As

Publication number Publication date
KR20170106360A (ko) 2017-09-20
SG11201705809QA (en) 2017-08-30
AU2016212091A1 (en) 2017-08-03
CA2973147A1 (en) 2016-08-04
EA201791696A1 (ru) 2017-11-30
WO2016120311A1 (en) 2016-08-04
JP2018503654A (ja) 2018-02-08
EP3250289A1 (en) 2017-12-06
CL2017001904A1 (es) 2018-03-23
ZA201704957B (en) 2018-12-19
CN107592811A (zh) 2018-01-16
US20180021347A1 (en) 2018-01-25
IL253390A0 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
SV2018005643A (es) Composiciones de insulina de rapida accion
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
DOP2016000253A (es) Nuevos compuestos
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
BR112018069900A2 (pt) composição antimicrobiana, método de limpeza ou desinfecção de uma superfície e uso de um complexo fosfolipídico catiônico
EP3292872A4 (en) COMPOSITION FOR THE TREATMENT OR PREVENTION OF INFECTIOUS INFLAMMATORY DISEASES OR COMPOSITION FOR IMMUNE REINFORCEMENT WITH TRYPTOPHANYL TRNA SYNTHETASE AS AN ACTIVE AGENT
WO2015001541A3 (en) Pharmaceutical film composition
BR112018004249A2 (pt) composto, e, composição para prevenção ou tratamento de doenças trombóticas.
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
BR112018007374A2 (pt) composição farmacêutica
MX2018013203A (es) Ciclodextrinas como procoagulantes.
BR112018007651A2 (pt) composição de limpeza antimicrobiana, método para a desinfecção de uma superfície e utilização de uma composição
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
BR112017011591A2 (pt) composição de liberação prolongada estável, processo para a preparação da composição de liberação prolongada
BR112016019002A2 (pt) composições para a prevenção e/ou o tratamento de patologias associadas a alfa-glicosidase

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]